By Helena Smolak
AstraZeneca posted increased first-quarter core earnings per share and sales that beat forecasts.
The Anglo-Swedish pharmaceutical giant said Thursday that its core earnings per share increased to $2.06 from $1.92 the prior-year period.
Total revenue rose 19% to $12.68 billion boosted by product sales and continued growth in Alliance Revenue from partnered medicines.
Analysts expected core earnings per share at $1.92 on sales of $11.84 billion, according to a company-compiled consensus.
AstraZeneca reiterated its full-year guidance.
Write to Helena Smolak at helena.smolak@wsj.com
(END) Dow Jones Newswires
04-25-24 0236ET